This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction In todays competitive pharmaceutical landscape, marketing strategies must evolve to meet changing customer expectations. Are you still relying on traditional marketing tactics, or have you embraced a more dynamic, omnichannel marketing approach? With healthcare providers (HCPs) and patients engaging across multiple digital and offline touchpoints, pharma brands that fail to adapt risk losing valuable market share.
Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program. As entities in the supply chain that don’t make medicine are increasingly using medicines to subsidize other parts of their business, patients and employers face increasing costs and barriers to accessing c
Day or night, Marc Cohen, a major donor to Dana-Farber Cancer Institute, had a direct line to one of its leading oncologists. No question was too big or too small, and almost no hour was off limits for a consultation. Cohen and his doctor, Kenneth C. Anderson, exchanged hundreds of emails and texts over two decades about Cohen’s disease, multiple myeloma, a rare and incurable blood cancer that is Anderson’s specialty.
Student Research Opportunities eomizowh Mon, 03/17/2025 - 13:52 Directed Study / Research Under the direction of a faculty member, students may earn Directed Research or Directed Study credits for special projects. Directed Study at the College of Pharmacy follows University of Minnesota policy , which generally requires an average workload of three hours per week per academic credit.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.
UK pharma group acquires Belgiums EsoBiotec as it announces EU has approved Imfinzi lung cancer drug Business live latest updates AstraZeneca has struck a $1bn (773m) deal to buy a Belgian biotech company that specialises in cancer immunotherapies, the latest in a string of acquisitions that also yielded positive results for a late-stage rare disease drug on Monday.
In a recent report, the U.S. Federal Trade Commission released an update on patent settlements between brand-name and generic drug makers, but for the first time, mentioned a maneuver used by these companies that may raise a different type of antitrust concern. These settlements can be traced to a law passed 40 years ago that was designed to speed the entry of lower-cost generics to the marketplace.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
In a recent report, the U.S. Federal Trade Commission released an update on patent settlements between brand-name and generic drug makers, but for the first time, mentioned a maneuver used by these companies that may raise a different type of antitrust concern. These settlements can be traced to a law passed 40 years ago that was designed to speed the entry of lower-cost generics to the marketplace.
AstraZeneca has agreed to acquire Belgian biotech EsoBiotec for up to $1 billion. The deal focuses on development of in vivo cell therapies, utilising EsoBiotecs Engineered NanoBody Lentiviral (ENaBL) platform. EsoBiotec will receive an initial payment of $425 million once the deal has closed, plus up to $575 million based on development and regulatory milestones.
SILVER SPRING, Md. — Most Food and Drug Administration employees were required to return to work in person on Monday. For some, the working conditions were less than ideal. At the main campus in Silver Spring, employees wondered whether the water was drinkable after testing in some buildings last fall revealed the presence of the Legionella bacteria.
Table of Contents Understanding the Importance of HCP Engagement in Pharma Marketing Key Marketing Strategies for Pharma Brands to Reach HCPs Optimizing Digital and Paid Media Strategies for Pharma Marketing Measuring Success: Tracking HCP Engagement and ROI Understanding the Importance of HCP Engagement in Pharma Marketing Engaging healthcare professionals (HCPs) effectively is a top priority for pharmaceutical brands.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! And happy St. Patrick’s Day. I grew up on the south shore of Boston, around what some call an “Irish riviera” — an area with a high proportion of families with Irish heritage, mine included.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Competitive intelligence is a powerful tool for navigating uncertainty and staying ahead in a rapidly shifting business landscape. This month, we explore how companies are using CI to drive innovation, improve decision-making, and uncover new growth opportunities. From real-world case studies in our upcoming webinar to key forces shaping the energy sector in 2025, we highlight the insights that matter.
Amid the Trump administration’s reshaping of America’s public health authorities, Eric Green, longtime director of the National Human Genome Research Institute, has abruptly left his role, according to two NHGRI employees with knowledge of the situation and internal communications reviewed by STAT. Green, who held that role for 16 years, is the first director of one of the National Institutes of Health’s 27 institutes to leave his position in President Trump’s second
Harvard Medical School professor Isaac Kohane remembers being asked, when he was a trainee doctor, to diagnose a child with low blood sugar in the intensive care unit. He delivered a beautifully comprehensive list of everything it could possibly be, he recalled — “Mwah!” Then his attending asked him a simple question: “When were the IVs switched?
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! We’re just a few days out from STAT’s Breakthrough Summit East !
At a press conference, WHO officials laid out the many ways countries around the world are being impacted in real-time by the U.S. withdrawal of crucial humanitarian aid.
Over the past several years, the Fierce Healthcare team has asked our readers to help us crown the biggest power players in the healthcare industry as well as the most overused and flimsy buzzwords | #FierceMadness is officially back for 2025, and this year we're looking to find the best company name in healthcare.
The partnership aims to improve the recovery and assessment of livers for transplantation by leveraging OrganOxs normothermic machine perfusion technology and ProCures surgical and logistical solutions.
Although dietary changes have historically been a key approach to managing eosinophilic esophagitis, their limitations highlight the need for pharmacologic treatments.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content